Sie suchten nach: tamoxifen (Englisch - Slowenisch)

tamoxifen
tamoksifen

tamoxifen), and generally have a better prognosis.
er-pozitivne (er+) rakave celice potrebujejo za svojo rast estrogen, zato se odzivajo na zdravljenje z zdravili, ki zavrejo učinke estrogena (npr.

tamoxifen (used against some forms of cancer),
tamoksifen (za zdravljenje nekaterih oblik raka),

in vitro, raloxifene did not interact with the binding of warfarin, phenytoin, or tamoxifen.
raloksifen ni vplival na vezavo varfarina, fenitoina ali tamoksifena in vitro.

no interaction was observed when ibandronic acid was administered concomitantly with tamoxifen, or melphalan/ prednisolone.
pri sočasnem jemanju ibandronske kisline s tamoksifenom, melfalanom ali prednizolonom niso opazili medsebojnega delovanja.

reproduction is authorised provided the source is acknowledged. progression and survival rates as the patients taking tamoxifen.
kakšne koristi je zdravilo fareston izkazalo med študijami?

any other medicine belonging to the group called serms, such as tamoxifen, toremifene, bazedoxifene and raloxifene.
vsa druga zdravila, ki sodijo v skupino zdravil, imenovanih serm, kot so tamoksifen, toremifen, bazedoksifen in raloksifen.

eau guidelines suggest the use of prophylactic breast radiation, tamoxifen or aromatase inhibitors to manage these symptoms, although they are not licensed in this use.
v smernicah eau je predlagano, da bi za urejanje teh simptomov uporabljali obsevanje prsi, tamoksifen ali zaviralce aromataze, čeprav slednji niso odobreni za uporabo v te namene.

pharmacokinetic interaction studies in postmenopausal women have demonstrated the absence of any interaction potential with tamoxifen or hormone replacement therapy (oestrogen).
16 farmakokinetične študije medsebojnega delovanja pri ženskah v postmenopavzi so pokazale, da s tamoksifenom ali hormonskim nadomestnim zdravljenjem (estrogenom) ne prihaja do medsebojnega delovanja.

in both arms, after the last cycle of chemotherapy, patients with positive estrogen and/or progesterone receptors received tamoxifen 20 mg daily for up to 5 years.
v obeh krakih so bolnice s pozitivnimi estrogenskimi in/ali progesteronskimi receptorji po zadnjem ciklu kemoterapije do 5 let dobivale tamoksifen 20 mg na dan.

concomitant osteoporosis therapy included: calcitonin, raloxifene, tamoxifen, hormone replacement therapy, tibolone; but excluded other bisphosphonates.
sočasno zdravljenje osteoporoze je vključevalo: kalcitonin, raloksifen, tamoksifen, hormonsko nadomestno zdravljenje, tibolon; uporaba drugih difosfonatov pri tem ni bila dovoljena.

in the her2-overexpressing population, only 2 patients were enrolled who had received prior trastuzumab, 2 patients had received prior aromatase inhibitor therapy, and approximately half had received tamoxifen.
v populaciji s čezmerno ekspresijo her2 sta bili vključeni le 2 bolnici, ki sta predhodno prejemali trastuzumab, 2 bolnici sta predhodno prejemali zaviralec aromataze in približno pol bolnic je prejemalo tamoksifen.

in both arms, after the last cycle of chemotherapy, patients with er+ and/or pgr+ tumours received tamoxifen 20 mg once a day for up to 5 years.
v obeh krakih so bolnice s pozitivnimi estrogenskimi in/ali progesteronskimi receptorji po zadnjem ciklu kemoterapije do 5 let dobivale tamoksifen 20 mg na dan.

drugs which require metabolic activation by cyp2d6 in order to be effective (e.g., tamoxifen), may have reduced efficacy when administered concomitantly with inhibitors of cyp2d6 such as bupropion.
zdravilom, ki za učinkovanje potrebujejo aktivacijo presnove z encimom cyp2d6 (npr. tamoksifen), se lahko zmanjša učinkovitost, če se uporabijo sočasno z zaviralci encima cyp2d6, kot je bupropion.

caution is advised in case of combination with cyp3a4 substrates having a narrow therapeutic margin i.e. immunosuppressive agents (cyclosporine, tacrolimus, sirolimus) as well as cyp3a4- metabolised cytotoxics, i.e. cyclophosphamide, etoposide, finasteride, ifosfamide, tamoxifen, vinca- alcaloids.
previdnost je potrebna pri kombinacijah substratov za cyp3a4 z majhno terapevtsko širino, t.j. pri imunosupresivnih sredstvih (ciklosporin, takrolimus, sirolimus), pa tudi pri citotoksičnih sredstvih, ki jih presnavlja cyp3a4, kot so ciklofosfamid, etopozid, finasterid, ifosfamid, tamoksifen, alkaloidi vinca.